Sort
40,608 grants matching “prostate cancer”
Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment Resistance
$910,254Moran Amit · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
DEVELOPEMNT OF NOVEL DRUGS THAT TARGET COACTIVATION SITES OF THE ANDROGEN RESEPTOR FOR TREATMENT OF ANTIANDROGEN0RESISTANT PROSTATE CANCER
$910,136The University Of British Columbia · · FY2012 · Department of Defense
Exploring Precision Oncology: From Gene Fusions to lncRNAs
$910,078Arul M Chinnaiyan · University Of Michigan At Ann Arbor · R35 · FY2022 · CA
Exploring Precision Oncology: From Gene Fusions to lncRNAs
$910,078Arul M Chinnaiyan · University Of Michigan At Ann Arbor · R35 · FY2023 · CA
Diazeniumdiolates as Broad-Spectrum Anticancer Agents
$909,984Larry K Keefer · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
IMPACT OF ONLINE PROSTATE CANCER INFORMATION ON HEALTH DISPARITIES
$909,666New York University · · FY2020 · Defense Health Agency
Interaction of Chemical Carcinogens and Chemotherapeutic Agents with DNA
$909,452Miriam C Poirier · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
CELL-PENETRATING BISPECIFIC ANTIBODIES FOR TARGETING ONCOGENIC TRANSCRIPTION FACTORS IN ADVANCED PROSTATE CANCER
$908,894The Medical University Of South Carolina · · FY2012 · Department of Defense
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research
$908,559Catherine M. Tangen · Fred Hutchinson Cancer Research Center · UM1 · FY2017 · CA
Leadership, Planning and Evaluation (LP&E)
$908,501Michael A Teitell · University Of California Los Angeles · P30 · FY2025 · CA
Vaccine and radiation for the therapy of human cancers
$908,412James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Vaccine and Drug Combination Therapy for Human Cancers
$908,412James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
CANCER AND LEUKEMIA GROUP B CCOP RESEARCH BASE
$908,401University Of Chicago · U10 · FY2001 · CA
Mechanisms of Normal Tissue Toxicity
$908,372Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: UCSF CLINICAL RESEARCH SITE APPLICATION
$907,929Regents Of The University Of California, San Francisco, The · · FY2022 · Defense Health Agency
Michigan-VUMC Biomarker Characterization Center
$907,751Arul M Chinnaiyan · University Of Michigan At Ann Arbor · U2C · FY2024 · CA
CREB ACTIVATION: A GENE SIGNATURE AND CONTROL SWITCH IN PROSTATE CANCER
$907,625University Of Arizona · · FY2017 · Department of the Army
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
$907,536Mary Christine Playdon · University Of Utah · U01 · FY2024 · CA
SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CA
$906,947University Of Texas Hlth Sci Ctr San Ant · U01 · FY2003 · CA
Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy
$906,883Martin W Brechbiel · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA
Tissue Processing-Sequencing Facility
$906,825Cathy D Vocke · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
$906,613Claudine Isaacs · Georgetown University · N01 · FY2010 · CA
TARGETING THE CELL SURFACEOME OF AGGRESSIVE NEUROENDOCRINE PROSTATE CANCER
$906,522Fred Hutchinson Cancer Research Center · · FY2017 · Defense Health Agency
Targeted Fluorescence Imaging of Nerves for Surgical Guidance
$906,421Cristina A Tan Hehir · General Electric Global Research Ctr · R01 · FY2012 · EB
DUKE UNIVERSITY TARGET-BASED CLINICAL RESEARCH PROGRAM IN PROSTATE CANCER
$906,184Duke University · · FY2008 · Department of Defense